House Dust Mite Extract (Acarizax ®) for Allergic Asthma. HTA ID: 20016

Assessment Status NCPE Assessment Process Complete
HTA ID 20016
Drug House Dust Mite Extract
Brand Acarizax ®
Indication Is indicated in adult patients (18-65 years) with HDM allergic asthma not well controlled by inhaled corticosteroids (ICS) and associated with mild to severe house dust mite allergic rhinitis. Diagnosis should be confirmed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE).
Assessment Process
Rapid review commissioned 12/03/2020
Rapid review completed 30/04/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract (Acarizax ®) for allergic asthma compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 07/05/2020
Pre-submission consultation with Applicant 08/06/2020
Full submission received from Applicant 28/04/2022
Preliminary review sent to Applicant 26/09/2022
NCPE assessment re-commenced 08/11/2022
Factual accuracy sent to Applicant 20/01/2023
NCPE assessment re-commenced 27/01/2023
NCPE assessment completed 24/02/2023
NCPE assessment outcome The NCPE recommends that House Dust Mite extract (Acarizax®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary